Text of section effective on April 01, 2025
Sec. 549.0107.  LIMITATIONS ON AGREEMENT TO ACCEPT PROGRAM BENEFITS INSTEAD OF SUPPLEMENTAL REBATES.  (a)  A commission agreement to accept a program benefit described by Section 549.0106:
(1)  may not prohibit the commission from entering into a similar agreement with another entity that relates to a different drug class;
(2)  must be limited to a period the commission expressly determines; and
(3)  subject to Subsection (b), may cover only a product that has received United States Food and Drug Administration approval as of the date the commission enters into the agreement.
(b)  A new product the United States Food and Drug Administration approves after the commission enters into the agreement may be incorporated into the agreement only under an amendment to the agreement.
Added by Acts 2023, 88th Leg., R.S., Ch. 769 (H.B. 4611), Sec. 1.01, eff. April 1, 2025.